Literature DB >> 7862981

Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia.

D J Yang1, S Wallace, A Cherif, C Li, M B Gretzer, E E Kim, D A Podoloff.   

Abstract

PURPOSE: To develop a hydrophilic ligand to image tumor hypoxia at positron emission tomography (PET).
MATERIALS AND METHODS: Biodistribution of fluorine-18-labeled fluoroerythronitroimidazole (FETNIM) and F-18-labeled fluoromisonidazole (FMISO) was determined at PET and autoradiography in three mammary-tumor-bearing rats. The partition coefficient of FETNIM, FMISO, and misonidazole was determined.
RESULTS: Biodistribution of F-18-labeled FETNIM at 1, 2, and 4 hours showed tumor-to-blood ratios of 2.29 +/- 0.599, 2.41 +/- 0.567 and 8.02 +/- 2.420, respectively, and tumor-to-muscle ratios of 0.66 +/- 0.267, 2.11 +/- 0.347, and 5.92 +/- 2.240, respectively. The tumor-to-blood count density ratio with F-18-labeled FETNIM at 4 hours after injection was significantly higher than with F-18-labeled FMISO. Autoradiographs indicated that both agents could help differentiate hypoxic versus necrotic region in the tumor.
CONCLUSION: F-18-labeled FETNIM can help detect tumor hypoxia and is easier to prepare, less costly, and more hydrophilic than F-18-labeled FMISO.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7862981     DOI: 10.1148/radiology.194.3.7862981

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  41 in total

Review 1.  Positron emission tomography (PET): expanding the horizons of oncology drug development.

Authors:  Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles R Thomas; John G Kuhn
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

2.  Imaging of tumour hypoxia using PET and 18F-labelled tracers: biology meets technology.

Authors:  Tove Grönroos; Heikki Minn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10       Impact factor: 9.236

Review 3.  Kinetic modeling in PET imaging of hypoxia.

Authors:  Fan Li; Jesper T Joergensen; Anders E Hansen; Andreas Kjaer
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-09-06

4.  GdDO3NI, a nitroimidazole-based T1 MRI contrast agent for imaging tumor hypoxia in vivo.

Authors:  Praveen K Gulaka; Federico Rojas-Quijano; Zoltan Kovacs; Ralph P Mason; A Dean Sherry; Vikram D Kodibagkar
Journal:  J Biol Inorg Chem       Date:  2013-11-27       Impact factor: 3.358

Review 5.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 6.  Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers.

Authors:  Austin R Pantel; David A Mankoff
Journal:  Cancer Lett       Date:  2016-05-16       Impact factor: 8.679

Review 7.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

Review 8.  Molecular imaging of hypoxia with radiolabelled agents.

Authors:  Gilles Mees; Rudi Dierckx; Christel Vangestel; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-30       Impact factor: 9.236

9.  Nitroimidazole conjugates of bis(thiosemicarbazonato)64Cu(II) - Potential combination agents for the PET imaging of hypoxia.

Authors:  Paul D Bonnitcha; Simon R Bayly; Mark B M Theobald; Helen M Betts; Jason S Lewis; Jonathan R Dilworth
Journal:  J Inorg Biochem       Date:  2009-10-24       Impact factor: 4.155

10.  Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)- N-(3,3,3-[(18)F]trifluoropropyl)acetamide, [(18)F]EF3.

Authors:  P Mahy; M De Bast; P H Leveque; J Gillart; D Labar; J Marchand; V Gregoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-10       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.